IOVA - Iovance Biotherapeutics, Inc. Latest News | Finranks

26.03.2026

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

20.03.2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on March 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,400 shares of Iovance's common stock to one new, non-executive employee.

12.03.2026

Why 2 Small Biotechs May Hold the Key to New Cancer Treatments

Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines aiming to address a specific type of cancer with particular dedicated mechanisms.

11.03.2026

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

06.03.2026

What's Going On With Iovance Biotherapeutics Stock On Friday?

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) stock is trading higher on Friday, with no news to justify the movement.

05.03.2026

Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036

Iovance Biotherapeutics' most important product has strong momentum right now. However, the company faces significant challenges that make the stock risky.

04.03.2026

Iovance Biotherapeutics: Short-Term Pain, Long-Term Gain - I'm Still Bullish After All These Years

Iovance Biotherapeutics (IOVA) remains a high-risk, high-reward play, with lifileucel (Amtagvi) now approved for advanced melanoma and 2025 company revenues of $264m. IOVA faces persistent losses, a precarious cash runway, and intense competition, but real-world efficacy and expanding treatment center networks support cautious optimism. Key 2026–2027 catalysts include potential approvals in NSCLC and first-line melanoma, with blockbuster ambitions hinging on successful clinical and regulatory milestones.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
IOVA	UBS	Neutral	undefined >> $2	May 16th 2025
IOVA	Truist	Hold	undefined >> undefined	May 12th 2025
IOVA	Citizens JMP	Market Perform	undefined >> undefined	May 9th 2025

Iovance Biotherapeutics, Inc. (IOVA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us